Table 2. . League table summarizing treatment comparisons for efficacy and safety outcomes.
| A. League table comparing the overall survival hazard ratios of tyrosine kinase inhibitors for EGFR-mutant NSCLC† | |||||
|---|---|---|---|---|---|
| Treatment | Osimertinib | Gefitinib | Erlotinib | Dacomitinib | Chemotherapy |
| Afatinib | 1.50 (0.68, 3.30) | 0.67 (0.43, 1.05) | 1.17 (0.71, 1.94) | 1.44 (0.65, 3.22) | 0.32 (0.21, 0.47)‡ |
| Osimertinib | 0.45 (0.23, 0.86)‡ | 0.78 (0.36, 1.69) | 0.96 (0.38, 2.45) | 0.21 (0.10, 0.44)‡ | |
| Gefitinib | 1.74 (1.15, 2.62)‡ | 2.14 (1.09, 4.18)‡ | 0.47 (0.34, 0.65)‡ | ||
| Erlotinib | 1.23 (0.56, 2.70) | 0.27 (0.19, 0.38)‡ | |||
| Dacomitinib | 0.22 (0.11, 0.46)‡ | ||||
| B. League table comparing the progression-free survival hazard ratios of tyrosine kinase inhibitors for EGFR-mutant NSCLC† | |||||
| Treatment | Osimertinib | Gefitinib | Erlotinib | Dacomitinib | Chemotherapy |
| Afatinib | 1.04 (0.44, 2.50) | 0.66 (0.40, 1.08) | 1.07 (0.61, 1.85) | 1.19 (0.49, 2.86) | 0.55 (0.35, 0.86)‡ |
| Osimertinib | 0.63 (0.31, 1.30) | 1.02 (0.44, 2.38) | 1.14 (0.41, 3.17) | 0.53 (0.24, 1.18) | |
| Gefitinib | 1.62 (1.04, 2.52)‡ | 1.80 (0.87, 3.72) | 0.83 (0.58, 1.19) | ||
| Erlotinib | 1.11 (0.48, 2.60) | 0.51 (0.36, 0.73)‡ | |||
| Dacomitinib | 0.46 (0.21, 1.04) | ||||
| C. League table comparing the objective response rate odds ratios of tyrosine kinase Inhibitors for EGFR-mutant NSCLC§ | |||||
| Treatment | Osimertinib | Gefitinib | Erlotinib | Dacomitinib | Chemotherapy |
| Afatinib | 1.29 (0.48, 3.50) | 1.61 (0.91, 2.84) | 1.18 (0.60, 2.30) | 1.39 (0.51, 3.78) | 5.69 (3.40, 9.54)¶ |
| Osimertinib | 1.25 (0.55, 2.82) | 0.91 (0.34, 2.43) | 1.07 (0.34, 3.43) | 4.40 (1.76, 11.01)¶ | |
| Gefitinib | 0.73 (0.42, 1.26) | 0.86 (0.38, 1.97) | 3.53 (2.33, 5.36)¶ | ||
| Erlotinib | 1.18 (0.44, 3.17) | 4.84 (3.03, 7.71)¶ | |||
| Dacomitinib | 4.10 (1.63, 10.32)¶ | ||||
| D. League table comparing the grade 3 or 4 adverse events odds ratios of tyrosine kinase inhibitors for EGFR-mutant NSCLC§ | |||||
| Treatment | Osimertinib | Gefitinib | Erlotinib | Dacomitinib | Chemotherapy |
| Afatinib | 5.99 (0.79, 45.39) | 4.29 (1.40, 13.10) | 3.22 (0.93, 11.13) | 1.48 (0.19, 11.73) | 0.75 (0.27, 2.10) |
| Osimertinib | 0.72 (0.13, 3.87) | 0.54 (0.08, 3.74) | 0.25 (0.02, 2.80) | 0.13 (0.02, 0.80)¶ | |
| Gefitinib | 0.75 (0.29, 1.95) | 0.35 (0.06, 1.97) | 0.18 (0.08, 0.37)¶ | ||
| Erlotinib | 0.46 (0.06, 3.36) | 0.23 (0.11, 0.49)¶ | |||
| Dacomitinib | 0.51 (0.08, 3.37) | ||||
†
Comparison are based on hazard ratios estimates between treatments, comparisons should be read from left to right, and the estimate is in the cell shared between the column defining-treatment and row defining treatment.
‡
Significant results (95% CI for Hazard Ratio does not include 1).
§
Comparison are based on odds ratios estimates between treatments, comparisons should be read from left to right and the estimate is in the cell shared between the column defining-treatment and row defining treatment.
¶
Significant results (95% CI for odds ratio does not include 1).
EGFR: EGF receptor; NSCLC: Non-small-cell lung cancer.